Source: Health Products Regulatory Authority (IE) Revision Year: 2019 Publisher: KARO PHARMA AB, Box 16184, 103 24 Stockholm, Sweden
Burinex 5 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. A white, flat, circular, uncoated, bevelled-edge tablet marked with a score line and ‘5 mg’ on one face. The score line is only to facilitate breakup for ease of swallowing and not to divide into equal doses. |
Each tablet contains 5 mg of Bumetanide.
Excipient with known effect: Each tablet contains 92 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Bumetanide |
Bumetanide is a potent loop diuretic with a rapid onset and a short duration of action. The primary site of action is the ascending limb of the loop of Henle where it exerts inhibiting effects on electrolyte reabsorption, causing its diuretic and natriuretic action. |
| List of Excipients |
|---|
|
Maize starch |
PVC/aluminium blister packs of 14 (physician’s sample), 30 and 56 tablets.
Not all pack sizes may be marketed.
KARO PHARMA AB, Box 16184, 103 24 Stockholm, Sweden
PA22650/001/002
Date of first authorisation: 01 April 1978
Date of latest renewal: 01 April 2008
| Drug | Countries | |
|---|---|---|
| BURINEX | Austria, Canada, France, Ireland, Malta, Netherlands, New Zealand, Singapore, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
